These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 20388947

  • 1. How to improve the safety of biologic therapy in Crohn's disease.
    Ferkolj I.
    J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
    [Abstract] [Full Text] [Related]

  • 2. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P, Van Assche G, Vermeire S.
    Aliment Pharmacol Ther; 2006 Feb 15; 23(4):451-63. PubMed ID: 16441465
    [Abstract] [Full Text] [Related]

  • 3. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 4. Infliximab use in luminal Crohn's disease.
    Richter JA, Bickston SJ.
    Gastroenterol Clin North Am; 2006 Dec 13; 35(4):775-93. PubMed ID: 17129813
    [Abstract] [Full Text] [Related]

  • 5. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ, Hanauer SB.
    Am J Gastroenterol; 2002 Dec 13; 97(12):2962-72. PubMed ID: 12492177
    [Abstract] [Full Text] [Related]

  • 6. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment.
    Nordgaard-Lassen I, Dahlerup JF, Belard E, Gerstoft J, Kjeldsen J, Kragballe K, Ravn P, Sørensen IJ, Theede K, Tjellesen L, Danish Society for Gastroenterology.
    Dan Med J; 2012 Jul 13; 59(7):C4480. PubMed ID: 22759856
    [Abstract] [Full Text] [Related]

  • 7. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
    Carroccio A, Di Prima L, Pirrone G, Ambrosiano G, Noto D, Cefalù AB.
    Recenti Prog Med; 2006 Feb 13; 97(2):108-12; quiz 122. PubMed ID: 16671277
    [Abstract] [Full Text] [Related]

  • 8. [Treatment of chronic inflammatory bowel diseases].
    Lémann M.
    Bull Acad Natl Med; 2007 Jun 13; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
    [Abstract] [Full Text] [Related]

  • 9. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
    Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM.
    Gut; 2004 Sep 13; 53(9):1363-5. PubMed ID: 15306601
    [Abstract] [Full Text] [Related]

  • 10. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.
    Orlando A, Mocciaro F, Civitavecchia G, Scimeca D, Cottone M.
    Dig Liver Dis; 2008 Jul 13; 40 Suppl 2():S236-46. PubMed ID: 18598995
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
    Lawrance IC, Radford-Smith GL, Bampton PA, Andrews JM, Tan PK, Croft A, Gearry RB, Florin TH.
    J Gastroenterol Hepatol; 2010 Nov 13; 25(11):1732-8. PubMed ID: 21039834
    [Abstract] [Full Text] [Related]

  • 13. Closing fistulas in Crohn's disease--should the accent be on maintenance or safety?
    Fiocchi C.
    N Engl J Med; 2004 Feb 26; 350(9):934-6. PubMed ID: 14985492
    [No Abstract] [Full Text] [Related]

  • 14. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
    Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B.
    Aliment Pharmacol Ther; 2009 Aug 26; 30(3):253-64. PubMed ID: 19438424
    [Abstract] [Full Text] [Related]

  • 15. Guidelines for treatment with infliximab for Crohn's disease.
    Hommes DW, Oldenburg B, van Bodegraven AA, van Hogezand RA, de Jong DJ, Romberg-Camps MJ, van der Woude J, Dijkstra G, Dutch Initiative on Crohn and Colitis (ICC).
    Neth J Med; 2006 Aug 26; 64(7):219-29. PubMed ID: 16929083
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L.
    Am J Gastroenterol; 2002 Sep 26; 97(9):2350-6. PubMed ID: 12358255
    [Abstract] [Full Text] [Related]

  • 18. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
    Doubremelle M, Bourreille A, Zerbib F, Heresbach D, Metman EH, Beau P, Gournay J, Galmiche JP.
    Gastroenterol Clin Biol; 2002 Nov 26; 26(11):973-9. PubMed ID: 12483127
    [Abstract] [Full Text] [Related]

  • 19. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar 26; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.